Acuitas Therapeutics
Acuitas Therapeutics is a Vancouver-based privately held biotech that develops proprietary lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, licensing it exclusively to pharma and biotech partners without developing its own drugs. The platform is clinically validated through two FDA-approved products, ONPATTRO and COMIRNATY.
- Company typePrivate
- Founded2009
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Acuitas Therapeutics does
Acuitas Therapeutics is a Vancouver-based, privately held biotechnology company founded in 2009 that develops and licenses lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics. Operating on a pure partnership model, the company does not develop its own drugs; instead it licenses its proprietary LNP platform to pharmaceutical and biotechnology partners across preclinical optimization, clinical development, regulatory approval, and commercialization. Revenue is generated through licensing, royalty, and collaboration agreements rather than direct product sales.
The company's core technology is a clinically validated LNP delivery platform underpinned by proprietary ionizable lipid formulations, including the trademarked ALC-315™ lipid, designed to enable intracellular delivery of mRNA, siRNA, gene therapy payloads, CRISPR-based constructs, and other nucleic acid modalities. The platform has been validated through two FDA-approved products: ONPATTRO® (Alnylam's siRNA therapeutic for hereditary transthyretin-mediated amyloidosis) and COMIRNATY® (Pfizer-BioNTech's mRNA COVID-19 vaccine). Thirty-three partnered clinical trials have been initiated in the last three years, and Acuitas scientists have contributed over 40 peer-reviewed publications in Science, Nature, and Cell in the past two years.
In January 2026, Acuitas acquired a majority stake in Montreal-based RNA Technologies & Therapeutics, adding RNA construct design IP and small-batch GMP-grade manufacturing capacity. Subsequent 2026 partnerships with Sanofi, Eli Lilly, Circio, and Genflow Biosciences extend the platform into CRISPR epigenetic silencing, in vivo CAR-T, and SIRT6 gene therapy, respectively. The company maintains a lean headcount of 11-50 employees and reaches a global customer base exclusively through direct strategic partnerships rather than traditional sales or distribution channels.
Acuitas Therapeutics firmographics
Firmographics- Name
- Acuitas Therapeutics
- Legal name
- Acuitas Therapeutics
- Website
- https://acuitastx.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Acuitas Therapeutics is a Vancouver-based privately held biotech that develops proprietary lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, licensing it exclusively to pharma and biotech partners without developing its own drugs. The platform is clinically validated through two FDA-approved products, ONPATTRO and COMIRNATY.
- Ownership category
- akta.pro rank
Acuitas Therapeutics industry classification
Industry- Product category
- Drug Delivery Technology / Nucleic Acid Therapeutics Enablement
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)
- akta.pro secondary industries
- Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)
Keywords
Where Acuitas Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Acuitas Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- LNP Technology Licensing and Partnership: Acuitas generates revenue through strategic partnerships with pharmaceutical and biotech companies, licensing their LNP delivery technology to enable the development of nucleic acid therapeutics, gene therapies, and vaccines. The company works with partners from preclinical optimization through clinical trials, regulatory approval, and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Acuitas Therapeutics product offering
Product offeringCore offering
Acuitas Therapeutics provides proprietary lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, enabling pharmaceutical and biotechnology partners to develop mRNA vaccines, gene therapies, CRISPR-based therapies, and RNAi drugs. The company does not develop its own drugs; instead it licenses its clinically validated LNP delivery platform and provides formulation, optimization, and development support to partners from preclinical optimization through clinical trials, regulatory approval, and commercialization.
Product overview
Acuitas Therapeutics offers a unified LNP delivery technology platform for nucleic acid therapeutics. The company does not develop its own drugs but provides its globally validated, best-in-class lipid nanoparticle delivery systems exclusively to pharmaceutical and biotechnology partners. The core platform includes proprietary lipid formulations such as ALC-315™ lipid, which is applied in cancer vaccines and prophylactic vaccines. Their technology has been used in two approved commercial products (ONPATTRO® and COMIRNATY®) and enabled over 33 clinical trials for partnered programs.
Differentiator
Problem solved
Functional benefit
Products and services
- LNP Delivery Technology Platform Core proprietary lipid nanoparticle (LNP) delivery technology platform enabling the intracellular delivery of nucleic acid payloads for pharmaceutical and biotechnology partners developing mRNA vaccines, gene therapies, CRISPR-based therapies, and RNAi drugs. The platform is clinically validated through two approved products and is licensed/exclusively used by partners from preclinical optimization through clinical trials, regulatory approval, and commercialization.
- ALC-315™ Lipid A novel proprietary ionizable lipid component used in LNP formulations designed to improve the potency and safety of mRNA therapies, with application in cancer vaccines and prophylactic vaccines.
Quantifiable outcome
- Two approved products on the market using Acuitas' LNP technology
- +1 more outcomes
Companies that use Acuitas Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Acuitas Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Acuitas Therapeutics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- SanoficoreStrategic collaboration for CRISPR-based epigenetic silencing therapy development using LNP delivery technology for STX-1150 targeting PCSK9 to lower LDL-C.
- Eli LillycoreStrategic collaboration for CRISPR-based epigenetic silencing therapy development using LNP delivery technology.
- Genflow BiosciencescoreGenflow Biosciences partnered with Acuitas Therapeutics to evaluate lipid nanoparticle delivery systems for its SIRT6 gene therapy platform. Under the agreement, Acuitas formulates Genflow's mRNA payload using its LNP platform for preclinical evaluation studies. The collaboration is fully funded by Acuitas with no cash consideration or dilution to Genflow shareholders, providing access to clinically proven delivery technology at no cost. Data generated from preclinical studies will inform future development decisions including delivery optimization and potential partnering arrangements for Genflow's SIRT6 platform targeting age-related diseases.
- CirciocoreAcuitas Therapeutics and Circio entered a technology evaluation agreement to assess whether Acuitas' lipid nanoparticle (LNP) technology can be combined with Circio's circular RNA expression platform (circVec) for novel in vivo CAR-T therapy targeting cancer and autoimmune diseases.
- RNA Technologies & TherapeuticscoreAcuitas acquired a majority stake in Montreal-based RNA Technologies & Therapeutics (RNA T&T), a company specializing in RNA construct design and manufacturing. The two Canadian biotech firms continue operating independently while gaining streamlined access to complementary optimization and manufacturing expertise for RNA-LNP therapeutics development. RNA T&T was co-founded by Nobel laureate Dr. Drew Weissman and scientist Dr. Mohamad-Gabriel Alameh, who notably contributed the RNA design for the first personalized CRISPR therapy administered to a patient. The investment enables RNA T&T to expand its operational footprint, further develop its proprietary algorithmic platform for RNA sequence optimization, and grow capabilities in small-batch GMP-grade production of personalized therapies.
Scale indicators4 records
Recent moves5 records
Expansion highlights6 records
Acuitas Therapeutics competitors and assessment
Company assessmentDirect peers
- Genevant Sciences: Genevant Sciences is a lipid nanoparticle delivery technology company that licenses its LNP platform to nucleic acid therapeutics developers. It is the most direct competitor to Acuitas in the LNP licensing business model, serving the same pharma/biotech partner base with overlapping ionizable-lipid chemistries.
- Arcturus Therapeutics: Arcturus develops its own LNP-enabled mRNA therapeutic candidates and also engages in LNP technology collaborations. It is a direct peer in that it both develops and out-licenses lipid nanoparticle delivery technology for nucleic acid payloads, competing for partner programs with Acuitas.
- Precision NanoSystems (a Danaher / Cytiva company): Precision NanoSystems develops LNP formulation technologies and instrumentation for nucleic acid delivery, serving pharma and biotech partners with both technology licensing and manufacturing scale-up services. Comparable to Acuitas as an LNP-focused platform provider with development and CDMO-adjacent capabilities.
Emerging players
- Sirnaomics: Sirnaomics develops RNAi therapeutics with proprietary polypeptide-based and nanoparticle delivery systems, including LNP-formulated candidates. Comparable as an emerging nucleic-acid-delivery player with overlapping target indications (oncology, fibrosis) and partner profile to Acuitas' licensees.
- eTheRNA immunotherapies: eTheRNA develops mRNA-based immunotherapies and is building internal lipid-based delivery capabilities for cancer and infectious-disease applications. Comparable to Acuitas as an emerging player in the RNA/LNP delivery space with a more therapeutics-oriented focus.
- Codiak BioSciences: Codiak developed exosome-based delivery platforms (engEx) for nucleic acid and protein payloads as an alternative to LNP. Comparable as a delivery-platform peer addressing the same therapeutic developers with a non-LNP alternative, providing competitive context on next-generation delivery modalities.
Broad incumbents
- Moderna: Moderna is a leading mRNA therapeutics company with an internal proprietary LNP platform used across its vaccine and therapeutic pipeline. It is a broad incumbent because, while it does not license LNP externally, its scale and in-house delivery R&D set the competitive benchmark for LNP performance.
- BioNTech: BioNTech co-developed COMIRNATY (one of the two FDA-approved products using Acuitas' LNP) and operates substantial internal LNP R&D. As a large oncology and infectious-disease mRNA company, BioNTech is comparable both as a partner/customer of Acuitas and as a competitor developing proprietary LNP alternatives.
- CureVac: CureVac is an mRNA therapeutics company with proprietary lipid nanoparticle and other delivery formulations used across its vaccine and oncology pipeline. Comparable as a peer that both develops its own LNP chemistry and competes for nucleic acid therapeutic partnerships.
- Alnylam Pharmaceuticals: Alnylam developed ONPATTRO using Acuitas' LNP and is the leading RNAi therapeutics company. It is comparable as Acuitas' first commercial LNP licensee and as a company actively pursuing alternative siRNA delivery chemistries (GalNAc conjugates) that could reduce reliance on LNP.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Acuitas Therapeutics social profiles
Digital presenceAcuitas Therapeutics compliance and trust
Trust signalCompliance2 records
Acuitas Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acuitas Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Acuitas Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Acuitas Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acuitas Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acuitas Therapeutics
What does Acuitas Therapeutics do?
Acuitas Therapeutics provides proprietary lipid nanoparticle (LNP) delivery technology for nucleic acid therapeutics, enabling pharmaceutical and biotechnology partners to develop mRNA vaccines, gene therapies, CRISPR-based therapies, and RNAi drugs. The company does not develop its own drugs; instead it licenses its clinically validated LNP delivery platform and provides formulation, optimization, and development support to partners from preclinical optimization through clinical trials, regulatory approval, and commercialization.
Is Acuitas Therapeutics a public or private company?
Acuitas Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Acuitas Therapeutics founded?
Acuitas Therapeutics was founded in 2009. It employs 11 to 50 people.
Where is Acuitas Therapeutics based?
Acuitas Therapeutics is headquartered in Vancouver, Canada, in the North America region.
How does Acuitas Therapeutics make money?
One revenue line is on record: LNP Technology Licensing and Partnership.
Who are Acuitas Therapeutics's main competitors?
Direct peers on record are Genevant Sciences, Arcturus Therapeutics and Precision NanoSystems (a Danaher / Cytiva company). Emerging players are Sirnaomics, eTheRNA immunotherapies and Codiak BioSciences. Broad incumbents are Moderna, BioNTech, CureVac and Alnylam Pharmaceuticals.
Does Acuitas Therapeutics have an API?
No public API is recorded for Acuitas Therapeutics.
What industry is Acuitas Therapeutics in?
Acuitas Therapeutics's product category is Drug Delivery Technology / Nucleic Acid Therapeutics Enablement. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods). Its NAICS code is 541714 and its SIC code is 2836.